NPP
ABBV icon

New Potomac Partners’s AbbVie ABBV Stock Holding History

New Potomac Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.08M Sell
20,685
-1,205
-6% -$225K 2.1% 13
2024
Q2 		$3.75M Buy
21,890
+345
+2% +$57.1K 2.05% 14
2024
Q1 		$3.92M Buy
21,545
+206
+1% +$35.5K 2.18% 10
2023
Q4 		$3.31M Buy
21,339
+160
+0.8% +$23.3K 1.97% 16
2023
Q3 		$3.16M Buy
21,179
+40
+0.2% +$5.87K 2.17% 13
2023
Q2 		$2.85M Sell
21,139
-55
-0.3% -$8.06K 1.88% 17
2023
Q1 		$3.38M Sell
21,194
-150
-0.7% -$22.9K 2.34% 9
2022
Q4 		$3.45M Buy
21,344
+24
+0.1% +$3.68K 2.55% 6
2022
Q3 		$2.86M Sell
21,320
-2,240
-10% -$321K 2.42% 10
2022
Q2 		$3.61M Sell
23,560
-65
-0.3% -$9.93K 2.9% 6
2022
Q1 		$3.83M Sell
23,625
-275
-1% -$39.9K 2.69% 8
2021
Q4 		$3.24M Buy
23,900
+35
+0.1% +$4.13K 2.1% 18
2021
Q3 		$2.57M Buy
23,865
+265
+1% +$30.3K 1.78% 26
2021
Q2 		$2.66M Buy
23,600
+80
+0.3% +$9.01K 1.81% 23
2021
Q1 		$2.54M Sell
23,520
-215
-0.9% -$23K 1.87% 23
2020
Q4 		$2.54M Sell
23,735
-1,000
-4% -$96.1K 1.84% 22
2020
Q3 		$2.17M Buy
24,735
+90
+0.4% +$8.47K 1.73% 25
2020
Q2 		$2.42M Sell
24,645
-740
-3% -$65.2K 2.16% 17
2020
Q1 		$1.93M Sell
25,385
-695
-3% -$59.2K 2.11% 18
2019
Q4 		$2.31M Buy
26,080
+12,200
+88% +$1.01M 2.15% 15
2019
Q3 		$1.05M Buy
13,880
+200
+1% +$13.7K 1.05% 41
2019
Q2 		$995K Sell
13,680
-620
-4% -$48.7K 1.01% 43
2019
Q1 		$1.15M Sell
14,300
-1,105
-7% -$90.4K 1.17% 40
2018
Q4 		$1.42M Buy
15,405
+90
+0.6% +$7.92K 1.53% 34
2018
Q3 		$1.45M Sell
15,315
-7,900
-34% -$749K 1.34% 39
2018
Q2 		$2.15M Sell
23,215
-345
-1% -$33.7K 2.08% 18
2018
Q1 		$2.23M Sell
23,560
-1,040
-4% -$114K 2.19% 13
2017
Q4 		$2.38M Buy
+24,600
New +$2.32M 2.27% 11

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

New Potomac Partners's ABBV Position: Q3 2024 in Review

New Potomac Partners reduced its AbbVie (ABBV) stake by 5.5% in Q3 2024, selling an estimated $225K and leaving 20,685 shares worth $4.08M. The position accounts for 2.1% of the portfolio, ranked #13.

New Potomac Partners first reported a position in ABBV in Q4 2017 and has held it in 28 quarters since. 3,504 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

  • New Potomac Partners held 20,685 shares of AbbVie worth $4.08M as of Q3 2024.
  • New Potomac Partners sold 1,205 AbbVie shares in Q3 2024, an estimated $225K.
  • AbbVie made up 2.1% of New Potomac Partners's portfolio in Q3 2024, its #13 holding.
  • New Potomac Partners first reported a position in AbbVie in Q4 2017 and has held it in 28 quarters since.
  • 3,504 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on New Potomac Partners's 13F filing for Q3 2024, filed 8 Nov 2024.